Study Comparing Two Different Tablet Formulations Of Bosutinib
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SKI-606 (Bosutinib)
- Registration Number
- NCT00934674
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study is comparing 2 formulations of bosutinib in healthy subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Men or women of non-childbearing potential, age 18 to 50 years.
Exclusion Criteria
- Any significant cardiovascular, renal, hepatic, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 SKI-606 (Bosutinib) Commercial Tablet manufactured by Excella 2 SKI-606 (Bosutinib) Clinical Tablet manufactured by Wyeth Montreal
- Primary Outcome Measures
Name Time Method Pharmacokinetics as measured by Cmax, AUC, tmax, and t1/2 2 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of bosutinib in targeting BCR-ABL and SRC family kinases in CML treatment?
How does bosutinib compare to imatinib in terms of efficacy and safety for chronic myeloid leukemia patients?
What are the key biomarkers used to assess bosutinib pharmacokinetics and bioavailability in phase 1 trials?
What adverse events are commonly associated with bosutinib formulations and how are they managed clinically?
What are the current combination therapies involving bosutinib and how do they enhance treatment outcomes in hematologic malignancies?